Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.
Target Price
The average target price of GHRS is 29 and suggests 122% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell